ATAI vs. CALT, GPCR, IOVA, SNDX, AUPH, SYRE, ELVN, MLYS, BGM, and NRIX
Should you be buying Atai Life Sciences stock or one of its competitors? The main competitors of Atai Life Sciences include Calliditas Therapeutics AB (publ) (CALT), Structure Therapeutics (GPCR), Iovance Biotherapeutics (IOVA), Syndax Pharmaceuticals (SNDX), Aurinia Pharmaceuticals (AUPH), Spyre Therapeutics (SYRE), Enliven Therapeutics (ELVN), Mineralys Therapeutics (MLYS), Qilian International Holding Group (BGM), and Nurix Therapeutics (NRIX). These companies are all part of the "pharmaceutical products" industry.
Atai Life Sciences vs.
Atai Life Sciences (NASDAQ:ATAI) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, community ranking, institutional ownership, risk, media sentiment, profitability, valuation, dividends and earnings.
Atai Life Sciences has a beta of 1.18, indicating that its stock price is 18% more volatile than the S&P 500. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the S&P 500.
28.4% of Atai Life Sciences shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 31.2% of Atai Life Sciences shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Atai Life Sciences has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Atai Life Sciences, indicating that it is currently the more affordable of the two stocks.
Atai Life Sciences received 307 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 66.53% of users gave Atai Life Sciences an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote.
Atai Life Sciences presently has a consensus price target of $9.00, suggesting a potential upside of 473.25%. Calliditas Therapeutics AB (publ) has a consensus price target of $39.25, suggesting a potential downside of 1.88%. Given Atai Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe Atai Life Sciences is more favorable than Calliditas Therapeutics AB (publ).
In the previous week, Atai Life Sciences had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Atai Life Sciences and 0 mentions for Calliditas Therapeutics AB (publ). Atai Life Sciences' average media sentiment score of 0.63 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Atai Life Sciences is being referred to more favorably in the media.
Atai Life Sciences has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Atai Life Sciences' return on equity of -65.75% beat Calliditas Therapeutics AB (publ)'s return on equity.
Summary
Atai Life Sciences beats Calliditas Therapeutics AB (publ) on 15 of the 18 factors compared between the two stocks.
Get Atai Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATAI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Atai Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATAI) was last updated on 3/28/2025 by MarketBeat.com Staff
